Ekso Bionics(TM) CEO Nathan Harding Interviewed Live, Monday August 4th on CNBC's Closing Bell
August 01 2014 - 7:00AM
Ekso Bionics Holdings, Inc. (OTCQB:EKSO) a robotic exoskeleton
company, today announced that CEO Nathan Harding will be
interviewed live by host Kelly Evans on CNBC Network's Closing
Bell. Any interested parties may tune in and listen live.
Date: Monday August 4, 2014
Start Time: 4:50 pm ET
Network: CNBC
Show: Closing Bell
Host: Kelly Evans
Live television
stream: http://www.cnbc.com/live-tv/
ANCHOR BIO:
Kelly Evans is co-anchor of CNBC's "Closing Bell." She joined
the network in February 2012 as an on-air correspondent, reporting
across CNBC's business day programming. Previously, Evans was
co-anchor of CNBC's "Squawk on the Street" as well as co-anchor of
CNBC's "Worldwide Exchange" based in London. Prior to CNBC,
Evans was a reporter and columnist for The Wall Street Journal,
penning the influential "Ahead of the Tape" column and writing for
"Heard on the Street." She also hosted the daily "News Hub" program
on WSJ.com and was a frequent guest on television and radio
networks, including CNBC. Evans joined the Journal in 2007 as a
reporter covering real estate and economics. Evans graduated
magna cum laude with a bachelor's degree from Washington & Lee
University in Lexington, Va., where she was a George Washington
Honor Scholar, a four-time scholar-athlete, and inducted into the
national leadership society, Omicron Delta
Kappa.
About Ekso Bionics
Since 2005, Ekso Bionics has been pioneering the field of
robotic exoskeletons, or wearable robots, to augment human
strength, endurance and mobility. The company's first commercially
available product called Ekso has helped thousands of people living
with paralysis take millions of steps not otherwise possible. By
designing and creating some of the most forward-thinking and
innovative solutions for people looking to augment human
capabilities, Ekso Bionics is helping people rethink current
physical limitations and achieve the remarkable.
Ekso Bionics is headquartered in Richmond, CA and is listed on
the OTC QB under the symbol EKSO. To learn more about Ekso Bionics
please visit us at www.eksobionics.com
Facebook: www.facebook.com/eksobionics
Twitter: @eksobionics
YouTube: http://www.youtube.com/user/EksoBionics/
Forward-Looking Statements
Any statements contained in this press release that do not
describe historical facts may constitute forward-looking
statements. Forward-looking statements may include, without
limitation, statements regarding (i) the plans and objectives of
management for future operations, including plans or objectives
relating to the design, development and commercialization of human
exoskeletons, (ii) a projection of income (including income/loss),
earnings (including earnings/loss) per share, capital expenditures,
dividends, capital structure or other financial items, (iii) the
Company's future financial performance and (iv) the assumptions
underlying or relating to any statement described in points (i),
(ii) or (iii) above. Such forward-looking statements are not
meant to predict or guarantee actual results, performance, events
or circumstances and may not be realized because they are based
upon the Company's current projections, plans, objectives, beliefs,
expectations, estimates and assumptions and are subject to a number
of risks and uncertainties and other influences, many of which the
Company has no control over. Actual results and the timing of
certain events and circumstances may differ materially from those
described by the forward-looking statements as a result of these
risks and uncertainties. Factors that may influence or
contribute to the inaccuracy of the forward-looking statements or
cause actual results to differ materially from expected or desired
results may include, without limitation, the Company's inability to
obtain adequate financing, the significant length of time and
resources associated with the development of our products and
related insufficient cash flows and resulting illiquidity, the
Company's inability to expand the Company's business, significant
government regulation of medical devices and the healthcare
industry, lack of product diversification, volatility in the price
of the Company's raw materials, existing or increased competition,
results of arbitration and litigation, stock volatility and
illiquidity, and the Company's failure to implement the Company's
business plans or strategies. These and other factors are
identified and described in more detail in the Company's filings
with the SEC, including, the Company's Current Report on Form 8-K/A
filed on March 31, 2014 and the Company's latest Form 10-Q filed on
May 13, 2014. The Company does not undertake to update these
forward-looking statements.
CONTACT: Media Contact:
Heidi Darling, Marketing Manager
Phone: 415.302.4777
hdarling@eksobionics.com
Investor Contact:
Lauren Glaser, Vice President
Phone: 646.378.2972
lglaser@troutgroup.com
Ekso Bionics (NASDAQ:EKSO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Ekso Bionics (NASDAQ:EKSO)
Historical Stock Chart
From Apr 2023 to Apr 2024